Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered Cell Therapies for the Treatment of HPV 16 E6-Expressing Cancers
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents and patent applications listed in the Supplementary Information section of this notice to MedGene Therapeutics, Inc. ("MedGene"), a company located in Silver Spring, Maryland, the United States of America.
Related coverage
- Takes of Marine Mammals Incidental to Specified Activities; Taking Marine Mammals Incidental to the City and Borough of Juneau's Seawalk Extension Project, Juneau, Alaska
- Colorado Underground Injection Control (UIC) Program; Class VI Primacy
- Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
- Notice of Agency Determination on Waiver With Respect to Land; Indianapolis Downtown Heliport, Indianapolis, Indiana
- Magnuson-Stevens Fishery Conservation and Management Act Provisions; Fisheries of the Northeastern United States; Framework Adjustment 7 to the Atlantic Spiny Dogfish Fishery Management Plan
- Magnuson-Stevens Act Provisions; Fisheries off West Coast States; Pacific Coast Groundfish Fishery; Pacific Coast Groundfish Fishery Management Plan; Fixed Gear Marking and Entanglement Risk Reduction